Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus vs Cyclophosphamide in Idiopathic Membranous Nephropathy
NCT00362531Phase 3Completed
- Sponsor
- Peking University
- Start
- Nov 2004
- Modality
- RNA-Targeting Small Molecules
01
Overview
Phase 3, randomised, open-label trial of tacrolimus in idiopathic membranous nephropathy (IMN) (2 arms), sponsored by Peking University. Primary endpoint: complete remission of renal disease at 12 months. Started Nov 2004; status: completed.
02
Drugs
tacrolimus
03
Conditions
idiopathic membranous nephropathy (IMN)
Beyond the preview
Go deeper on NCT00362531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00362531.